TeneoTwo is a hematological cancer product developer focused on developing new drugs for potential B-cell hematological malignancies, including diffuse large B-cell lymphoma and follicular lymphoma. Recently, AstraZeneca (AZN.O) announced that it will acquire TeneoTwo for as much as $1.27 billion to strengthen its blood disease cancer product line. The transaction is expected to close in the third quarter of 2022.
This article is reprinted from: https://www.itjuzi.com/merger/9061
This site is for inclusion only, and the copyright belongs to the original author.